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Abstract
Introduction: Rheumatoid arthritis (RA) is an inflammatory disease associated with accelerated atherosclerosis and
high risk of cardiovascular (CV) disease. Since genome-wide association studies demonstrated association between
rs599839 polymorphism and coronary artery disease, in the present study we assessed the potential association of
this polymorphism with endothelial dysfunction, an early step in atherogenesis.
Methods: A total of 128 RA patients without history of CV events were genotyped for rs599839 A/G
polymorphism. The presence of endothelial dysfunction was assessed by brachial ultrasonography (brachial flow-
mediated endothelium-dependent (FMD)).
Results: Patients carrying the allele G exhibited more severe endothelial dysfunction (FMD%: 4.61 ± 3.94%) than
those carrying the wild allele A (FMD%: 6.01 ± 5.15%) (P = 0.08). Adjustment for gender, age at the time of study,
follow-up time and classic CV risk factors disclosed a significant association between the rs599839 polymorphism
and FMD (G vs. A: P = 0.0062).
Conclusions: Our results confirm an association of the rs599839 polymorphism with endothelial dysfunction in RA.
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Introduction
Rheumatoid arthritis (RA) is a complex polygenic auto-
immune inflammatory disease with high risk of cardio-
vascular (CV) complications [1]. This is a consequence
of accelerated atherosclerosis [1]. Besides classic CV risk
factors and chronic systemic inflammation, recent stu-
dies have emphasized the relevance of several genetic
polymorphisms, such as HLA-DRB1 and TNF, in the
susceptibility to CV disease in RA [2,3].
A major issue in the process of accelerated athero-
sclerosis in RA is the development of endothelial dys-
function, an early step in the development of
atherosclerosis. An important step forward might be to
identify high-risk RA patients who would benefit from
active therapy to prevent clinical disease. Several nonin-
vasive imaging techniques provide the opportunity to
study the relationship of surrogate markers to the devel-
opment of atherosclerosis. Among them, ultrasound
techniques based on flow velocity are considered effi-
cient ways to measure subclinical atherosclerosis. Using
brachial artery ultrasonography assessment, we and
others have disclosed the presence of endothelial dys-
function expressed by abnormal levels of flow-mediated
endothelium-dependent vasodilatation (FMD) in patients
without clinically evident CV disease who had either
long-standing RA [4] or early-onset RA [5]. We also dis-
closed that the presence of endothelial dysfunction in
RA was at least in part genetically determined [4].
Genome-wide association studies (GWAS) aimed to
predict coronary artery disease (CAD) revealed several
novel putative loci that may increase the risk of CAD in
the general population. In this regard, the polymorphism
rs599839 (A > G) seems to be associated with CAD [6,7]
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and with higher plasma total and low-density lipoprotein
(LDL) cholesterol levels [8-10]. The non-coding
rs599839 variant is located near three coding genes on
chromosome lp13.3 genomic region [11]. Physically, the
closest genes are PSRC1, encoding for “proline/serine-
rich coiled coil protein 1”, and CELSR2, encoding for
the “cadherin EGF LAG seven-pass G-type receptor 2”.
Also, located at chromosome 1p13.3 is the SORT1 gene,
encoding for a cell surface receptor (sortilin) with multi-
ligand capabilities that has been implicated in insulin
mediated glucose uptake. Although rs599839 is located
in a non-codificant region, there is strong linkage dise-
quilibrium between rs599839 and variants located within
the 3’ end of the adjacent CELSR2 gene, including var-
iants with potential functional effects [7]. Although it is
postulated that this protein is a receptor involved in
contact-mediated communication, its specific function
has not been fully clarified.
Results obtained by GWAS, need to be validated with
replication studies in different cohorts to confirm these
findings [12].
Taking all these considerations together we aimed to
determine, for the first time, the potential role of
rs599839 polymorphism in the development of endothe-
lial dysfunction in a cohort of RA patients without clini-
cally evident CV disease.
Materials and methods
Patients and study protocol
A series of 128 Spanish RA patients recruited from Lugo
(NW Spain) with no previous history of CV disease were
included in the present study. The study was approved
by the ethics committee of the Hospital Xeral-Calde
(Lugo) and a subject’s written consent was obtained in
all the cases. All patients fulfilled the 1987 American
College of Rheumatology criteria for the classification of
RA [13]. Information on the main characteristics and
CV risk factors of the patients enrolled in the study is
shown in Table 1.
Genotyping
DNA from patients was obtained from peripheral blood
using standard methods.
The rs599839 A/G polymorphism was genotyped with
TaqMan SNP genotyping assays (C____972962_10) in a
7900 HT real-time polymerase chain reaction (PCR) sys-
tem, according to the conditions recommended by the
manufacturer (Applied Biosystem, Foster City, CA,
USA). Negative controls and duplicate samples were
included to check the accuracy of genotyping.
Brachial artery reactivity
Endothelial function was determined using high-sensitiv-
ity brachial ultrasonography according to the guidelines
for the ultrasound assessment of endothelial-dependent
FMD% [4,14]. B-mode scan of the right brachial artery,
in a longitudinal section 2 to 12 cm proximal to the
antecubital fossa, was performed in supine participants
using a vascular software for two-dimensional imaging,
color and spectral Doppler, an internal electrocardio-
gram (EKG) monitor, and a 7.5-MHz phased-array
transducer Hewlett-Packard SONOS 5500 system (Hew-
lett-Packard, Palo Alto, CA, USA). The anterior and
posterior intima-media interfaces were used to define
the baseline artery diameter, calculated as the average of
measurements made during four cardiac cycles at end
diastole. Timing of each image frame with respect to the
cardiac cycle was determined with simultaneous EKG
recordings on the ultrasound system digital monitor.
During image acquisition, anatomic landmarks were
noted to maintain the same image of the artery through-
out the study using a specific stereotactic clamp. The
forearm blood pressure cuff was inflated on the ipsilat-
eral wrist to at least 50 mm Hg above resting systolic
blood pressure for five minutes, and then was released.
FMD% (an increase in brachial artery diameter) was
measured 30 to 60 seconds after cuff release. To assess
endothelium-independent vasodilatation (NTG%), we
used 400 micrograms of sublingual nitroglycerin, which
acts directly on vessel smooth muscle to cause vasodila-
tation. NTG% was measured four minutes after nitrogly-
cerin intake. In all cases a cardiologist (CG-J) analyzed
all of the ultrasound data offline. A FMD value < 7%
was considered pathologic, indicating the presence of
endothelial dysfunction [14]. Intraobserver variability for
FMD and NTG was 1.3% and 1.9%, respectively, based
on repeat brachial ultrasonography in 32 individuals.
Assessment of the endothelial function of RA patients
Table 1 Main characteristics of the RA patients included
in the study
Clinical Feature % (n/N)
Patients 128
Main characteristics
Age at the time of disease onset (years, mean ± SD) 50 ± 13.5
Follow-up (years, mean ± SD) 12.9 ± 7.8
Percentage of women 76.9
Rheumatoid factor positive 76.5 (98/128)
Anti-CCP antibodies positive 67.2 (86/128)
Shared epitope positive 70.3 (90/128)
Cardiovascular risk factors
Hypertension 26.5 (34/128)
Diabetes mellitus 7.8 (10/128)
Dyslipidemia 19.5 (25/128)
Obesity 4.6 (6/128)
Smoking habit 10.9 (14/128)
Anti-CCP antibodies, anti-cyclic citrullinated peptide antibodies; RA,
rheumatoid arthritis; SD, Standard deviation.
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undergoing anti-TNF-a therapy was performed 24 to 48
hours before drug administration.
Statistical analysis
The association between the genotypes of the rs599839
polymorphism and surrogate markers of subclinical
atherosclerosis was tested using unpaired t test to com-
pare between two groups, and one-way analysis of var-
iance (ANOVA) to compare among more than two
groups. We also tested the association between these
parameters and alleles using analysis of covariance
(ANCOVA) adjusting for gender, age, duration of the
disease at the time of the ultrasonographic study and
traditional CV risk factors (hypertension, diabetes melli-
tus, dyslipidemia, obesity and a smoking habit).
Statistical significance was defined as P < 0.05. All
analyses were performed with STATA statistical soft-
ware 9.1 (Stata Corp., College Station, TX, USA).
Results
Results of the comparison between the different geno-
types and alleles of rs599839 polymorphism according
to surrogate markers of subclinical atherosclerosis are
shown in Table 2. Patients carrying the allele G exhib-
ited more severe endothelial dysfunction (FMD%: 4.61 ±
3.94%) than those carrying the wild allele A (FMD%:
6.01 ± 5.15%). However, the difference was slightly out
of the range of significance (P = 0.08). Likewise, values
of NTG% showed a similar trend with a marginal
decrease of NTG% in patients carrying the allelic variant
G compared with those carrying allele A (P = 0.06).
Also, RA patients carrying the GG and AG genotypes
had lower FMD% values (1.94 ± 3.98% and 5.35 ±
3.70%, respectively) than those homozygous for the AA
genotype (6.15 ± 5.42%). However, the difference did
not achieve statistical significance. It was also the case
when genotypes were assessed according to NTG%
results (Table 2).
Since gender, age at the time of ultrasonography
study, follow-up time and classic CV risk factors may
act as potential confounders of the results derived from
the ultrasonography assessment; adjustment for these
potential confounders was performed. Following this
procedure, a comparison of FMD and NTG values in
RA patients according to rs599839 alleles in an adjusted
ANCOVA model yielded a significant association
between the rs599839 A/G polymorphism and FMD and
NTG (G versus A: FMD% P = 0.0062 and NTG% P =
0.041, respectively).
Discussion
GWA studies have become a powerful approach to
rapidly identifying genetic variants that influence sus-
ceptibility to common complex diseases. Novel putative
loci, such as the rs599839 A/G polymorphism (chromo-
some 1p13.3), that seem to increase the risk to CAD
have been described by this method [6,7]. This rs599839
polymorphism has also been implicated in the presence
of higher plasma total and LDL cholesterol levels [8-10].
Since GWAS have to be validated by replication stu-
dies in different cohorts and endothelial dysfunction, an
early step in the atherogenesis, has been described in
patients with RA, we assessed for the first time the asso-
ciation between the rs599839 A/G polymorphism and
the presence of endothelial dysfunction in a series of RA
patients without clinically evident CV disease. Interest-
ingly, an adjusted analysis disclosed that the presence of
the mutant allele G was associated with the presence of
endothelial dysfunction.
Impaired FMD of the brachial artery due to endothe-
lial dysfunction has been associated with both CV risk
factors and future CV morbidity and mortality in the
general population [15]. In addition, endothelial dys-
function manifested by impaired FMD was observed in
both long-standing RA patients [4] and early-onset RA
patients [5] without clinically evident CV disease. These
observations support a potential role of FMD in estab-
lishing the presence of endothelial dysfunction as a sub-
clinical marker of atherosclerotic disease in RA. The
results derived from this study suggest a potential impli-
cation of the rs599839 polymorphism in the develop-
ment of endothelial dysfunction in RA. They also
support the claim of a genetic influence in the develop-
ment of the atherosclerotic disease in RA.
Conclusion
Our results showed that rs599839 polymorphism is
associated with the presence of endothelial dysfunction
in patients with RA.
Table 2 Comparison of FMD and NTG values in RA
patients according to rs599839 polymorphism
FMD%
mean ± SD (n)
P NTG%
mean ± SD (n)
P
rs599839
Allele
A 6.01 ± 5.15 (210) 0.08 16.95 ± 8.14 (210) 0.06
G 4.61 ± 3.94 (46) 14.52 ± 6.92 (46)
Genotype
AA 6.15 ± 5.42 (87) 0.16 17.34 ± 8.34 (87) 0.19
AG 5.35 ± 3.70 (36) 15.04 ± 7.01 (36)
GG 1.94 ± 3.98 (5) 12.66 ± 6.99 (5)
AG+GG 4.93 ± 3.85 (41) 0.20 14.74 ± 6.96 (41) 0.09
FMD, flow-mediated endothelium-dependent (post-ischemia) vasodilatation;
NTG, flow-mediated endothelial independent (post-nitroglycerin)
vasodilatation; RA, rheumatoid arthritis; SD, standard deviation
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